People discuss BPC-157 and TB-500 as alternatives, although they are not: BPC-157 is a fifteen amino acid fragment of a gastric protein studied mainly for its effects on blood vessels and the gut lining, and TB-500 is a fragment of thymosin beta-4, a protein whose main job is binding actin inside cells. In short, different biology, different papers, different forms.
The comparison also covers less than the internet suggests, because no head-to-head human trial has ever compared the two, and TB-500 has no human clinical trial data at all. But anyone telling you one beats the other for a specific injury goes beyond what researchers have published. So what you can compare is the evidence base, and that is what follows.
In This Guide
- Same shelf, different biology
- The head-to-head table
- What researchers have studied in each
- Where the comparison breaks down
- Regulatory and anti-doping status
- FAQ
Same shelf, different biology
TB-500 is a synthetic fragment of thymosin beta-4, which is a protein that most cells contain. Its best understood function is actin sequestration: it binds the monomeric form of actin and holds it unpolymerised, which keeps a pool of raw material available for cells to reshape their cytoskeleton when they migrate, divide or respond to injury. The proposed reason it appears in wound healing research follows from that, since cell migration is the first step in tissue repair.
BPC-157 comes from a different starting point, a fragment of a protein in gastric juice, and its research profile centres on the nitric oxide system and on vascular growth signalling such as VEGF. Because the two mechanisms explain different things, “which is stronger” is the wrong question, and “what has each actually been shown to do, in which species” is the right one.
The head-to-head table
| BPC-157 | TB-500 (thymosin beta-4 fragment) | |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Synthetic fragment of thymosin beta-4, a naturally occurring cellular protein |
| Proposed main mechanism | Nitric oxide signalling and vascular growth factors | Actin sequestration, supporting cell migration and cytoskeletal remodelling |
| Half-life | Under 30 minutes in animals. No human figure published | Not established in humans at all |
| Forms studied | Injectable, with oral and rectal dosing in the bowel trials | Injectable in animal work |
| Human trial data | Phase II work in inflammatory bowel disease, early 2000s | None for TB-500 itself; the parent protein has human trial data in wound healing |
| Animal evidence | Extensive, more than 30 studies reviewed between 1993 and 2024 | Broad in preclinical models, and mapped in a 2026 scoping review |
| Approved for human use | No | No |
| Anti-doping status | Prohibited, named in WADA S0 | Prohibited as a non-approved substance |
| Flagged by the FDA for compounding | Yes, with immunogenicity and impurity concerns stated | Yes, the FDA lists the beta-4 fragment with the same kind of concerns |
What researchers have studied in each
| Area | BPC-157 | TB-500 |
|---|---|---|
| Gut lining and inflammatory bowel disease | Human phase II data, the strongest human signal for either compound | Not the focus of the published work |
| Tendon and ligament | Animal models | Animal models, including work on tendon cell migration |
| Muscle injury | Animal models | Animal models |
| Skin and wound closure | Animal models | Preclinical models, with human trial data for the parent protein rather than the fragment |
| Nerve tissue | Animal models | Limited preclinical work |
| Heart and blood vessels | Animal models, consistent with the vascular mechanism | Preclinical work, including cardiac models |
| Strength or muscle growth in humans | Nothing published | Nothing published |
The pattern in that table is the honest summary of the pair. Both have real preclinical literature, neither has a human endpoint behind the claims gyms make for it, and only one has any human trial data at all.
Where the comparison breaks down
- No head-to-head studies. Because nobody has run a trial of one against the other in any species, every “X beats Y” claim is an inference from separate literatures.
- Different endpoints. For instance, the BPC-157 human data is about bowel inflammation. If the question is tendon healing, that data does not transfer, and the tendon evidence is animal data for both compounds.
- Different half-lives, and both remain poorly characterised. While one is under 30 minutes in animals, the other has no published human figure at all. Half-life does not predict effect duration in either case, for the reasons set out in our peptide half-life chart.
- Different purity risks. Both remain unapproved, so the certificate of analysis and the batch matter more than the compound choice does.
- The parent protein is not the fragment. Thymosin beta-4 has human trial data in some wound settings, but TB-500 is only a fragment of it, and that data does not automatically apply to a different molecule with a different half-life.
Regulatory and anti-doping status
The FDA, the EMA and the MHRA have not approved either compound for human use. Both appear on the FDA’s page of bulk drug substances for use in compounding that may present significant safety risks, where the stated concerns for each are immunogenicity for certain routes of administration and the difficulty of characterising peptide impurities. And both are prohibited in sport: WADA names BPC-157 specifically in its prohibited list under S0, the class for non-approved substances, and it prohibits TB-500 as a non-approved substance.
As with any research peptide, the practical question is not the label on the box but whether a batch-matched certificate of analysis exists, and whether the purity method and the peptide mass are stated. For the wider picture of categories and verification, see the guide to peptides, HGH and HCG and the other guides in the peptides section.
FAQ
Which is better, BPC-157 or TB-500?
Because no study has compared them head to head, in humans or in animals, the literature cannot answer that question. What you can compare is the evidence base, and BPC-157 has more of it, including the only human trial data in the pair.
Do they work the same way?
No. TB-500 comes from thymosin beta-4, whose best understood function is binding actin to support cell migration. BPC-157’s research profile instead centres on nitric oxide signalling and vascular growth factors. So they differ in mechanism and in origin.
Are either of them approved for human use?
Neither has FDA, EMA or MHRA approval, and the FDA lists both among compounding substances that may present significant safety risks.
Does TB-500 have human trials?
Not for TB-500 itself, since no trial has studied it. The parent protein, thymosin beta-4, has human trial data in some wound healing settings, and that is not the same molecule. TB-500 has no human clinical trial record of its own, because nobody has studied it in people.
Would you stack them?
That is a question about using unapproved substances, and this page will not answer it. There is no human data on co-administration of either compound, with each other or with anything else, and nobody can derive dosing information from animal studies.
Are they banned in sport?
Yes, both. WADA names BPC-157 explicitly in its S0 category of non-approved substances, and it prohibits TB-500 as a non-approved substance. So an inadvertent positive test is a real risk for a competing athlete.
What is the half-life of each?
BPC-157 sits under 30 minutes in animal studies, and nobody has published a human figure. Meanwhile, TB-500 has no established human half-life at all. But neither number tells you how long the effect lasts.
Which one is safer?
Neither has a human safety database of the kind an approved medicine has, so a ranking is not available. Still, both carry the same class of regulatory concern about immunogenicity and impurities.
Last reviewed: October 2026 by Julian Hart. This page is educational and is not medical advice, and it is not an endorsement or an instruction for using any substance. No regulator has approved either compound for human use, and anything involving dosing or a health condition belongs with a qualified clinician.
Sources
- McGuire FP, et al. Thymosin beta-4 and TB-500 in tissue healing, regeneration and musculoskeletal research: a scoping review. 2026.
- Maar K, et al. Utilizing developmentally essential secreted peptides: thymosin beta-4 in organ regeneration and repair. 2021.
- Xing Y, et al. Progress on the function and application of thymosin beta-4, including human trial data for the parent protein. 2021.
- McGuire FP, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. 36 studies, 1993 to 2024.
- He L, et al. Pharmacokinetics … of BPC-157 in rats and dogs. 2022.
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks, listing both BPC-157 and the thymosin beta-4 fragment.
- WADA. The Prohibited List, S0 non-approved substances.
- ClinicalTrials.gov searches for BPC-157 and TB-500, for the registry record cited in this article.
